The Eurazeo Mid-large buyout team1 has been supporting the company as a majority shareholder since 2019 and under its ownership, DORC has become one of the world-leading ophthalmic surgery platforms leading the growth game in the Vitreoretinal (“VR”) and Cataract market.

Our multidisciplinary French region team consisting of lawyers, tax advisers and civil law notaries have assisted Eurazeo on this transaction, alongside Latham & Watkins Paris. 

Closing of the transaction remains subject to completion of the relevant information and consultation process with the employee representative body of the company and applicable regulatory approvals.